April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
More
April 2, 2013
Bloomberg NewsPresident Obama on Tuesday announced a campaign designed to develop treatments for some of the least understood brain disorders,
an effort that could benefit health care giants Eli Lilly and Co. and others.
More
February 18, 2013
Bloomberg NewsRoche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders,
may gain the most from a U.S. government boost in funding to fully map the human brain.
More
January 18, 2013
Associated PressResearchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's
possible to prevent Alzheimer's disease in older people at high risk of developing it.
More
January 16, 2013
Associated PressEuropean regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's
disease.
More
December 17, 2012
J.K. WallEli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published
new research that the pharmaceutical company thinks confirms it is on the right track.
More
October 19, 2012
Bloomberg NewsResearchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts
to find a cure have been unsuccessful.
More
October 10, 2012
Bloomberg NewsEli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s
trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
More
October 8, 2012
J.K. WallEli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease,
according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than
5 percent on the news.
More
October 6, 2012
Scott OlsonThe 36-room wing at Hoosier Village Retirement Center includes antiques and minimizes confusing shadows among other design
elements.
More
August 27, 2012
Bloomberg NewsWhile investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression
early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
More
August 24, 2012
J.K. WallThe surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly
and Co., but it raised as many questions as it answered.
More
August 24, 2012
Bloomberg News, J.K. WallEli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials.
However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some
patients.
More
August 11, 2012
J.K. WallOdds are long that Eli Lilly and Co.'s leading Alzheimer's drug will show positive results when its Phase 3 trial results
are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a
home run for Lilly.
More
August 7, 2012
IBJ Staff and Bloomberg NewsPfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second
trial failure. Eli Lilly is developing a similar treatment.
More
July 24, 2012
Bloomberg NewsBapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to
target a cause for Alzheimer’s, rather than just its symptoms.
More
July 11, 2012
Bloomberg NewsJohnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available
drug designed to target a cause of Alzheimer's, rather than just its symptoms. Analysts say the potential drugs are long shots.
More
May 13, 2012
Bloomberg NewsTreatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may
pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs
that attack the same protein as Roche’s experimental drug.
More
May 7, 2012
J.K. WallFor more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a
huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward
the drugmaker’s diabetes portfolio.
More
April 9, 2012
J.K. WallThe agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with
Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
More
December 7, 2011
Bloomberg NewsEli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s
experimental Alzheimer’s drug could double the share price.
More
November 1, 2011
J.K. WallThe grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research
to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.
More
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
More
October 10, 2011
J.K. WallRemaining grant money will be invested to beef up the infrastructure of the Indiana Network for Patient Care, a health information
exchange operated by the Indianapolis-based Regenstrief Institute.
More
July 19, 2011
Bloomberg NewsEli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug
semagacestat didn’t improve after dosing was halted.
More
Three Magi
Cats out of the bag. The object of the game is to get acquired. That means the company has no idea how to grow beyond a certain point. Email is a 1990s technology. I have laughed at this company since day one. Such a small bit player. If it was anywhere but here, it wouldn't be newsworthy.
Esther, Indy has passed Chicago in the local government corruption arena. Don't downgrade us. We're No. 1 in the Midwest.
Does the buyer get to keep the recent Accu-Chek J.D. Power award? Be careful, those Swiss cannot be trusted. Last June they pimped Mayor Ballard and former Governor Daniels at a media op, announcing plans to invest "$300 million at its Indianapolis headquarters, creating up to 100 new jobs by 2017," only to turn around and close the Roche Nutley, NJ facility and eliminate 1000 jobs there later the same week. It seems that healthcare can be innovated only as long as money is to be made. Right now Roche seems to have big eyes for China: there are many Chinese in China and potential billions in Swiss francs! Since Roche is having difficulty with US insurance companies swallowing the bill for overpriced cancer drugs (with debatable efficacy) why not sell insurance to the Chinese and market the drugs to them there? There is a name for these sort of business practices however proper decorum precludes it use in this forum.
Same kind of Luddites who oppose I-69. Guessing their 501(c)(4) application probably sailed right through the IRS.